生物活性：Clopidogrel-d3 (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Clopidogrel-d3 hydrogen sulfate 相关抗体:
Cytochrome C Antibody
Cytochrome P450 17A1 Antibody
Aromatase Antibody
CYP11A1 Antibody
Cytochrome P450 1B1 Antibody (YA1836)
Adrenodoxin Antibody (YA2005)
Cytochrome P450 27A1 Antibody (YA2163)
Cytochrome P450 2C9 Antibody (YA2166)
Cytochrome P450 2E1 Antibody (YA2302)
Cytochrome P450 Reductase Antibody (YA2619)
Thromboxane A Synthase Antibody (YA2670)
P2Y12 Antibody (YA3135)
Cytochrome P450 3A4 Antibody (YA3365)
HSD11B1 Antibody (YA3376)
Cytochrome P450 17A1 Antibody (YA786)
CYP2E1 Antibody
CYP1A2 Antibody
PLSCR3 Antibody (YA1672)
P2Y6 Antibody (YA1691)
PROX1 Antibody (YA1754)
Cytochrome P450 4A Antibody (YA2087)
Cytochrome P450 24A1 Antibody (YA2121)
Cytochrome P450 26A1 Antibody (YA2259)
COX5B Antibody (YA2550)
Steroidogenic Factor 1 Antibody (YA3166)
Dynein Light Chain Tctex Type 1 Antibody (YA3263)
Cytochrome P450 2D6 Antibody (YA3384)
分子量：422.92
Formula：C16H15D3ClNO6S2
CAS 号：1217643-68-9
非标记 CAS：120202-66-6
中文名称：硫酸氢氯吡格雷-d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (530 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
 [Content Brief]
[2]. Katsunobu Hagihara, et al. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, Clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008;23(6):412-20.
 [Content Brief]
[3]. Jean-Marc Herbert, et al. P2Y12, a new platelet ADP receptor, target of Clopidogrel.Semin Vasc Med. 2003 May;3(2):113-22.
 [Content Brief]
[4]. Hai-Lu Wu, et al. Increased endoplasmic reticulum stress response is involved in Clopidogrel-induced apoptosis of gastric epithelial cells. PLoS One. 2013 Sep 13;8(9):e74381.
 [Content Brief]
[5]. Ran Ni, et al. Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model.Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2338-2344.
 [Content Brief]
[6]. Kuszynski DS, et al. Clopidogrel treatment inhibits P2Y2-Mediated constriction in the rabbit middle cerebral artery [published online ahead of print, 2021 Oct 1]. Eur J Pharmacol. 2021;174545.
 [Content Brief]